Caris Adds Capecitabine Response Signature to AI Tumor Board Report
Caris Life Sciences has introduced a proprietary AI Insights breast cancer signature for capecitabine in its Molecular Tumor Board Report, leveraging over 2,000 expression and copy number features from Whole Exome and Whole Transcriptome Sequencing. The new signature predicts first-line HER2-negative breast cancer patient response to the oral chemotherapy drug.
1. New AI-Driven Breast Cancer Signature
Caris Life Sciences has expanded its Molecular Tumor Board Report by adding a proprietary AI Insights signature specifically for predicting capecitabine response in HER2-negative breast cancer patients.
2. Technical Foundation and Methodology
The signature analyzes more than 2,000 expression and copy number features derived from Whole Exome and Whole Transcriptome Sequencing to forecast first-line chemotherapy outcomes for each individual patient.
3. Strategic and Commercial Implications
Offered as a research-use-only report alongside MI Cancer Seek, this development leverages Caris’ clinico-genomic database and FDA-approved sequencing platform to strengthen its precision medicine portfolio and potentially drive adoption in oncology research and clinical settings.